Galectin Therapeutics Inc. (NASDAQ:GALT), a pharmaceutical company focused on the development of treatments for fibrotic disease and cancer with a market capitalization of $76.57 million ...

Feb. 18, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced additional results showing a ...

Most cells in the body send out little messengers called extracellular vesicles that carry proteins, lipids, and other ...

New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaksBOSTON, ...

(RTTNews) - Galectin Therapeutics, Inc. (GALT), on Tuesday, announced additional data from the NAVIGATE trial showing a significant 68.1% reduction in the incidence of new varices in U.S. patients ...

Galectin Therapeutics (NASDAQ:GALT) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents. This met the analyst estimate for EPS of ...

Galectin Therapeutics (GALT) announced additional results showing a statistically significant reduction in new varices in per-protocol patients enrolled in the U.S. from the NAVIGATE trial for ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

This graphic illustrates paracrine adhesion signaling on small extracellular vesicles, which secretes a protein called galectin-3, which promotes endocytosis so the vesicle can be absorbed into the ...

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts ...